Lobe Sciences (LOBE) AI Stock Analysis

• Market Cap: C$18.86M
• Dividend Yield: N/A
• Average Volume (3M): 19.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.11
• Revenue Growth: -100.00%
• EPS Growth: -8.70%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 269,487,120
• 10 Day Avg. Volume: 13,139
• 30 Day Avg. Volume: 19,648
• PEG Ratio: 0.13
• Price to Book (P/B): 2.94
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: C$0.05 ▼(-10.00% Downside)
• Action: Reiterated Date: 03/13/26
• Date: Action: Reiterated 03/13/26

The score is primarily held down by weak financial performance (no revenue, ongoing losses, and persistent cash burn), with only modest balance-sheet leverage as a partial offset. Technical indicators are broadly neutral with a mild upward bias, but valuation remains unfavorable due to losses (negative P/E) and no dividend support.

Positive Factors

Modest Leverage

Modest debt relative to equity (debt-to-equity ~0.19 TTM) reduces near-term financing pressure for an early-stage biotech. Lower leverage preserves optionality for R&D funding, partnerships, or milestone-based financing and reduces bankruptcy risk over the medium term.

Improving Cash Flow Trend

TTM free cash flow shows improvement versus the prior annual period, suggesting operational progress or cost control. If sustained, this directional improvement can extend runway, lessen near-term dilution needs, and make the company a more credible partner for licensing or collaborations.

Strategic Focus in Mental Health/CNS

A concentrated strategy on mental health/CNS and psychedelic-related therapeutics targets a large unmet medical need and growing scientific and regulatory interest. This niche can attract specialized investors, research collaborations, and licensing opportunities if clinical milestones are met.

Negative Factors

No Revenue and Ongoing Losses

TTM results show no product revenue and material operating losses (EBIT ~ -$5.0M; net loss ~ -$4.5M). Without revenue, the company relies on external capital or deals to fund operations, increasing execution risk and making long-term viability contingent on successful clinical progress or financing events.

Persistent Cash Burn

Operating and free cash flows are substantially negative (~ -$1.75M TTM) and have been cash-burning for multiple years. Continued negative cash generation constrains R&D investment timing, forces recurring fundraising, and raises the probability of dilutive financings that can impair shareholder value.

Historical Equity Instability

Reported equity volatility and prior negative equity (2023–2024) point to past dilution or recapitalizations. This history increases the likelihood of future dilutive financings or weakened covenant positions, reducing investor protections and signaling structural balance-sheet fragility.

Lobe Sciences Business Overview & Revenue Model

Company Description

Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.

Lobe Sciences Financial Statement Overview

Summary

Financials indicate elevated risk: TTM shows no revenue and material losses (EBIT about -$5.0M; net loss about -$4.5M) with consistently negative operating/free cash flow (about -$1.75M). Balance sheet leverage is modest (debt-to-equity ~0.19 TTM), but multi-year equity instability (including prior negative equity) and ongoing cash burn keep overall financial strength weak.

Income Statement

TTM (Trailing-Twelve-Months) results show no revenue and continued material operating losses (EBIT about -$5.0M; net loss about -$4.5M). The company’s revenue profile has been highly inconsistent over the last several years (including periods of near-zero sales and sharp declines), and profitability remains structurally negative with persistent losses across periods. The main positive is that the TTM net loss is slightly narrower than the prior annual period, but the lack of revenue and ongoing negative earnings keep income-statement quality very weak.

Balance Sheet

The balance sheet appears less leveraged in the most recent periods, with modest debt relative to equity in TTM (debt-to-equity ~0.19) and the latest annual period (~0.12), which helps reduce near-term financial risk. However, equity has been volatile and previously turned negative (2023–2024), indicating historical balance-sheet strain and potential dilution/recapitalization dynamics. Total assets increased sharply versus 2024, improving reported scale, but the multi-year equity instability is a key weakness.

Cash Flow

Cash generation remains a major concern: TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are both meaningfully negative (about -$1.75M), and the company has consistently burned cash over multiple years. While free cash flow improved versus the prior annual period (positive growth rate in TTM), cash flow still does not cover losses and points to ongoing funding needs. The primary strength is the direction of improvement, but the absolute level of cash burn remains high.

Breakdown	Nov 2025	Nov 2024	Aug 2023	Nov 2022	Nov 2021
Income Statement
Total Revenue	0.00	136.21K	840.53K	0.00	0.00
Gross Profit	0.00	134.45K	772.83K	-10.22K	0.00
EBITDA	-4.27M	-4.12M	-4.40M	-11.96M	-6.16M
Net Income	-4.43M	-4.42M	-4.71M	-12.25M	-22.82M
Balance Sheet
Total Assets	7.59M	258.57K	2.30M	1.75M	12.10M
Cash, Cash Equivalents and Short-Term Investments	7.54M	237.77K	140.29K	907.54K	7.43M
Total Debt	273.35K	1.75M	332.64K	0.00	0.00
Total Liabilities	2.70M	3.37M	2.46M	1.30M	804.70K
Stockholders Equity	2.36M	-3.11M	-160.13K	445.69K	11.29M
Cash Flow
Free Cash Flow	-1.42M	-462.29K	-1.72M	-2.73M	-5.04M
Operating Cash Flow	-1.42M	-462.29K	-1.72M	-2.73M	-5.04M
Investing Cash Flow	6.56M	0.00	0.00	1.74M	1.07M
Financing Cash Flow	514.40K	563.51K	950.01K	753.12K	4.92M

Lobe Sciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.06
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LOBE, the sentiment is Positive. The current price of 0.06 is below the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.06, and above the 200-day MA of 0.05, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 59.70 is Neutral, neither overbought nor oversold. The STOCH value of 42.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:LOBE.

Lobe Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OILS	61 Neutral	C$9.29M	8.94	11.57%	―	-1.14%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LOBE	46 Neutral	C$18.86M	-2.55	―	―	-100.00%	-8.70%
AVCN	46 Neutral	C$21.99M	-5.08	-68.32%	―	2.41%	74.61%
LABS	45 Neutral	C$27.35M	-3.68	-19.10%	―	18.06%	34.58%
PCLO	44 Neutral	C$10.76M	5.19	―	―	15.64%	58.47%
GWAY	41 Neutral	C$21.26M	-44.16	-2.15%	―	19.66%	84.34%

Lobe Sciences Corporate Events

Lobe Sciences Names Mirza Rahimani as Chief Financial Officer

Lobe Sciences has promoted Mirza Rahimani to Chief Financial Officer, effective March 2, 2026, after he had been providing financial advisory services to management and the board since December 2025. Rahimani replaces former CFO Yong Yao, who served through an arrangement with Century Biolabs Inc.

Rahimani brings more than 15 years of experience in accounting, financial reporting, corporate governance, and corporate development across life sciences, mining, and technology sectors. The company’s leadership highlights his track record in public-company compliance, strategic transactions and financings as a key asset to support Lobe’s growth plans and execution of its biopharmaceutical strategy.

The most recent analyst rating on (TSE:LOBE) stock is a Sell with a C$0.06 price target. To see the full list of analyst forecasts on Lobe Sciences stock, see the TSE:LOBE Stock Forecast page.

Lobe Sciences Ramps Up R&D on Psilocin-Based Therapeutic as Cash Position Remains Solid

Lobe Sciences reported first-quarter fiscal 2026 results showing a sharp ramp-up in research and development spending to approximately $982,000 as it accelerated work on lead candidate L-130 through its Cynaptec subsidiary, while maintaining a cash position of nearly $6 million, short-term investments of about $1 million, and net working capital just over $4 million. The higher R&D investment, focused on preclinical, clinical and regulatory activities for L-130 and progress on S-100 for sickle cell disease, contributed to a wider quarterly net loss of roughly $1.3 million, but management highlighted improved operating efficiency, tight cash controls and expanded scientific resources as evidence that the company is scaling its development pipeline in a disciplined manner ahead of planned Phase 1 and Phase 2 clinical work.

The most recent analyst rating on (TSE:LOBE) stock is a Hold with a C$0.06 price target. To see the full list of analyst forecasts on Lobe Sciences stock, see the TSE:LOBE Stock Forecast page.

Lobe Sciences Bolsters Board with Capital Markets Expert as It Builds on 2025 Momentum

Lobe Sciences has strengthened its board of directors with the appointment of corporate and securities lawyer Nick Karakochuk, whose expertise in mergers and acquisitions, capital markets, and governance is expected to support the company’s strategic growth initiatives following momentum built in fiscal 2025. As part of his appointment, Karakochuk received 3.5 million restricted share units, underscoring the company’s intent to align governance and capital markets capabilities with its clinical-stage biopharmaceutical ambitions in rare and orphan neurological and psychiatric diseases, including the development of its proprietary L-130 compound through majority-owned Cynaptec Pharmaceuticals.

The most recent analyst rating on (TSE:LOBE) stock is a Hold with a C$0.07 price target. To see the full list of analyst forecasts on Lobe Sciences stock, see the TSE:LOBE Stock Forecast page.

Lobe Sciences Strengthens Balance Sheet and Refocuses Pipeline After Leadership Overhaul

Lobe Sciences reported a substantial improvement in its fiscal 2025 financial position following a leadership transition and board renewal, with cash rising to $5.9 million, new short-term investments of $1.7 million, and working capital swinging from a deficit to a $5.2 million surplus, while eliminating its current portion of convertible notes and significantly reducing derivative liabilities. Despite a slightly higher net loss attributable to the parent company, the strengthened balance sheet, simplified corporate structure, and focused investment in core subsidiaries are expected to reduce liquidity risk and better support business development, as the company advances its L-130 CNS therapeutic program under Cynaptec and prioritizes S-100 for sickle cell disease through Altemia, positioning Lobe to pursue value-accretive transactions and partnerships aligned with shareholder interests.

The most recent analyst rating on (TSE:LOBE) stock is a Hold with a C$0.04 price target. To see the full list of analyst forecasts on Lobe Sciences stock, see the TSE:LOBE Stock Forecast page.